Parmax Pharma Peer Comparison

BSE: 540359

₹131.15

₹1.25 (0.96%)

As on 24-Aug-2026IST

Market cap

₹49 Cr

Revenue (TTM)

₹18 Cr

P/E Ratio

--

P/B Ratio

-10.5

Div. Yield

0 %

Edit

	Parmax Pharma	IEL	Vasundhara Rasayan	Himadri Speciality	Deepak Nitrite
Market cap (₹ Cr)	49	75	50	33,955	24,047
Revenue (₹ Cr)	18	1	35	4,974	8,575
Net Profit (₹ Cr)	-1.19	1.49	5.90	804.14	783.41
Net Margin (%)	-5.82	67.60	15.67	15.54	9.08
RoE (%)	--	3.36	14.76	18.21	13.96
Price to Earnings	--	50.27	8.40	42.49	30.70
Price-To-Book	-10.54	1.65	1.19	6.88	3.89

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Parmax Pharma	IEL	Vasundhara Rasayan	Himadri Speciality	Deepak Nitrite
Operating Revenue	18.39	1.47	35.09	4,974.29	8,574.79
Total Income	20.51	2.21	37.68	5,175.21	8,624.11
Total Expenditure	20.90	0.36	28.94	3,969.25	7,243.44
EBITDA	-2.51	1.11	6.15	1,005.04	1,331.35
Depreciation	1.25	0.02	0.46	74.82	237.05
EBIT	-3.76	1.09	5.69	930.22	1,094.30
Interest	1.24	0.07	0.32	70.95	60.80
Other Income	2.12	0.74	2.59	200.92	49.32
Exceptional Items	0.00	0.00	0.00	0.00	-12.84
Profit before Tax	-2.88	1.76	7.97	1,060.19	1,069.98
Provision for Tax	-1.69	0.27	2.06	256.05	286.57
Profit after Tax	-1.19	1.49	5.90	804.14	783.41

Liabilities (₹ Cr)

	Parmax Pharma	IEL	Vasundhara Rasayan	Himadri Speciality	Deepak Nitrite
Shareholder's Funds	-6.15	45.01	40.88	4,706.68	5,836.83
Minority Interest	0.00	0.00	0.00	-4.97	-0.15
Non-Current Liabilities	11.52	1.46	0.41	308.16	1,532.66
Current Liabilities	22.68	0.62	6.60	1,236.15	1,278.74
Total Liabilities	18.75	46.92	43.07	5,100.22	7,706.02

Assets (₹ Cr)

	Parmax Pharma	IEL	Vasundhara Rasayan	Himadri Speciality	Deepak Nitrite
Non-Current Assets	11.38	12.06	2.36	3,202.99	5,145.91
Current Assets	16.68	35.04	45.34	2,823.52	3,069.38
Total Assets	18.75	46.92	43.07	5,100.22	7,706.02
Total Debt*	8.09	0.90	4.21	308.70	1,170.53
Net Current Assets	-6.00	34.42	38.74	1,587.37	1,790.64
Contingent Liabilities	--	0.41	1.09	50.60	0.53

Cashflow (₹ Cr)

	Parmax Pharma	IEL	Vasundhara Rasayan	Himadri Speciality	Deepak Nitrite
Cash From Operating Activities	-0.96	2.11	-5.83	446.86	624.70
Cash Flow from Investing Activities	-0.70	-20.97	0.46	-235.20	-1,491.33
Cash from Financing Activities	1.40	43.67	1.35	-271.49	806.16
Net Cash Inflow / Outflow	-0.26	24.81	-4.02	-59.84	-60.47

Ratios

Profitability Ratios

	Parmax Pharma	IEL	Vasundhara Rasayan	Himadri Speciality	Deepak Nitrite
ROCE (%)	-29.88	2.44	16.58	22.17	17.00
ROE (%)	0.00	3.36	14.76	18.21	13.96
ROA (%)	-5.10	3.18	12.98	14.67	9.55
EBIT Margin (%)	-20.44	74.42	16.22	18.70	12.76
Net Margin (%)	-5.82	67.60	15.67	15.54	9.08
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Parmax Pharma	IEL	Vasundhara Rasayan	Himadri Speciality	Deepak Nitrite
Revenue Growth (%)	21.10	261.18	3.45	9.80	7.12
EBIT Growth (%)	-111.89	228.86	81.36	9.36	41.57
Net Profit Growth (%)	64.45	344.12	50.00	31.47	29.05
EPS Growth (%)	51.58	290.99	50.00	27.82	30.59
Book Value Growth (%)	-346.40	3,563.74	11.34	19.46	12.34

Valuation Ratios

	Parmax Pharma	IEL	Vasundhara Rasayan	Himadri Speciality	Deepak Nitrite
Price / Earnings	0.00	50.27	8.40	42.29	30.34
Price / Book Value	-5.86	1.65	1.19	6.88	3.89
Dividend Yield (%)	0.00	0.00	1.28	0.12	0.43
EV/EBITDA	80.88	45.59	7.53	33.69	18.86
Market Cap (₹ Cr)	15.80	61.28	73.37	20,933.97	27,044.64

Solvency Ratios

	Parmax Pharma	IEL	Vasundhara Rasayan	Himadri Speciality	Deepak Nitrite
Debt to Equity	-1.87	0.02	0.01	0.00	0.19
Short term debt to equity ratio	--	--	0.10	0.08	0.03
Current Ratio	0.74	56.24	6.87	2.28	2.40
Quick Ratio	0.39	56.24	6.64	1.67	1.73
Interest Coverage	-1.32	24.78	26.21	15.94	18.60

Operating Efficiency Ratios

	Parmax Pharma	IEL	Vasundhara Rasayan	Himadri Speciality	Deepak Nitrite
Debtors to sales (%)	17.20	25.24	21.25	14.00	17.56
Asset Turnover	0.79	0.03	0.77	0.91	1.05
Receivable days	20.01	49.30	55.72	50.98	56.28
Inventory Days	36.94	0.00	19.39	50.95	36.90
Payable days	149.20	74.11	45.04	46.50	33.64
Cash Conversion Cycle	-92.25	-24.81	30.08	55.43	59.53

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly